Coresh J, Astor B, Sarnak MJ. Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. 2004; 13:73–81.

• PubMed
Coresh J, Astor B, Sarnak MJ. Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. 2004; 13:73–81.)| false
• Search Google Scholar
• Export Citation

Culleton, BF, et al.. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. 1999; 56:2214–2219.

• PubMed
Culleton, BF, . Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. 1999; 56:2214–2219.)| false
• Search Google Scholar
• Export Citation

Dries DL, et al.. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681–689.

• Crossref
• PubMed
Dries DL, . The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681–689.10.1016/S0735-1097(99)00608-7)| false
• Search Google Scholar
• Export Citation

Garg, AX, et al.. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61:1486–1494.

• Crossref
• PubMed
Garg, AX, . Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61:1486–1494.10.1046/j.1523-1755.2002.00270.x)| false
• Search Google Scholar
• Export Citation

Go AS, et al.. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296–1305.

• Crossref
• PubMed
Go AS, . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296–1305.10.1056/NEJMoa041031)| false
• Search Google Scholar
• Export Citation

Henry RM, et al.. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402–1407.

• Crossref
• PubMed
Henry RM, . Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402–1407.10.1111/j.1523-1755.2002.kid571.x)| false
• Search Google Scholar
• Export Citation

van Dokkum RP, et al.. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 2004; 15:3103–3110.

• Crossref
• PubMed
van Dokkum RP, . Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 2004; 15:3103–3110.10.1097/01.ASN.0000145895.62896.98)| false
• Search Google Scholar
• Export Citation

Doty JM, et al.. Effect of increased renal venous pressure on renal function. 1999; 4:1000–1003.

• PubMed
Doty JM, . Effect of increased renal venous pressure on renal function. 1999; 4:1000–1003.)| false
• Search Google Scholar
• Export Citation

Malbrain ML, et al.. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med 2006; 32:1722–32.

• Crossref
• PubMed
Malbrain ML, . Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med 2006; 32:1722–32.10.1007/s00134-006-0349-5)| false
• Search Google Scholar
• Export Citation

Damman K, et al.. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:582–8.

• Crossref
• PubMed
Damman K, . Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:582–8.10.1016/j.jacc.2008.08.080)| false
• Search Google Scholar
• Export Citation

Schlaich MP, et al.. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932–4.

• Crossref
• PubMed
Schlaich MP, . Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932–4.10.1056/NEJMc0904179)| false
• Search Google Scholar
• Export Citation

St John Sutton M, et al.. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997; 96:3294–9.

• Crossref
• PubMed
St John Sutton M, . Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997; 96:3294–9.10.1161/01.CIR.96.10.3294)| false
• Search Google Scholar
• Export Citation

Vaziri ND, et al.. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003; 63:179–85.

• Crossref
• PubMed
Vaziri ND, . Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003; 63:179–85.10.1046/j.1523-1755.2003.00702.x)| false
• Search Google Scholar
• Export Citation

Martin FL, et al.. B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin 2008; 4:449–54.

• Crossref
• PubMed
Martin FL, . B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin 2008; 4:449–54.10.1016/j.hfc.2008.03.011)| false
• Search Google Scholar
• Export Citation

Boerrigter G, Lapp H, Burnett JC. Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol 2009; 191:485–506.

• Crossref
• PubMed
Boerrigter G, Lapp H, Burnett JC. Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol 2009; 191:485–506.10.1007/978-3-540-68964-5_21)| false
• Search Google Scholar
• Export Citation

Cataliotti A, et al.. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin 2006; 2:269–76.

• Crossref
• PubMed
Cataliotti A, . Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin 2006; 2:269–76.10.1016/j.hfc.2006.09.002)| false
• Search Google Scholar
• Export Citation

Mohammed SF, et al.. Nesiritide in acute decompensated heart failure: current status and future perspectives. Rev Cardiovasc Med 2008; 9:151–8.

• PubMed
Mohammed SF, . Nesiritide in acute decompensated heart failure: current status and future perspectives. Rev Cardiovasc Med 2008; 9:151–8.)| false
• Search Google Scholar
• Export Citation

Lisy O, et al.. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008; 52:60–8.

• Crossref
• PubMed
Lisy O, . Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008; 52:60–8.10.1016/j.jacc.2008.02.077)| false
• Search Google Scholar
• Export Citation

Lee CY, et al.. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009; 49:668–73.

• Crossref
• PubMed
Lee CY, . Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009; 49:668–73.10.1177/0091270009336233)| false
• Search Google Scholar
• Export Citation

McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease. Curr Heart Fail Rep 2010.

• Crossref
• PubMed
McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease. Curr Heart Fail Rep 2010.10.1007/s11897-010-0016-6)| false
• Search Google Scholar
• Export Citation

Rubattu S, et al.. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21:733–41.

• Crossref
• PubMed
Rubattu S, . Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21:733–41.10.1038/ajh.2008.174)| false
• Search Google Scholar
• Export Citation

Best PJ, et al.. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002; 55:375–84.

• Crossref
• PubMed
Best PJ, . Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002; 55:375–84.10.1016/S0008-6363(02)00402-9)| false
• Search Google Scholar
• Export Citation

Pan S, et al.. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci USA, 2009; 106:11282–7.

• Crossref
• PubMed
Pan S, . Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci USA, 2009; 106:11282–7.10.1073/pnas.0811851106)| false
• Search Google Scholar
• Export Citation

Dickey DM, Burnett JC Jr., Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008; 283:35003–9.

• Crossref
• PubMed
Dickey DM, Burnett JC Jr., Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008; 283:35003–9.10.1074/jbc.M804538200)| false
• Search Google Scholar
• Export Citation